Figures & data
Table 1 Baseline characteristics of studies included in the network meta-analysis
Figure 3 Comparisons of efficacy in terms of disease control rate in advanced HCC scheme.
Abbreviations: HAIC, hepatic arterial infusion chemotherapy; OR, odds ratio; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; RT, radiotherapy.
![Figure 3 Comparisons of efficacy in terms of disease control rate in advanced HCC scheme.](/cms/asset/4341f0bd-f8d2-479a-a726-d7ef971b64e7/dtcr_a_162898_f0003_c.jpg)
Figure 4 Comparisons of efficacy in terms of median OS in advanced HCC.
Abbreviations: HAIC, hepatic arterial infusion chemotherapy; OR, odds ratio; OS, overall survival; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; RT, radiotherapy.
![Figure 4 Comparisons of efficacy in terms of median OS in advanced HCC.](/cms/asset/92b3465c-6b2e-4758-8577-c74f3d45d211/dtcr_a_162898_f0004_c.jpg)
Figure 5 Rankogram of interested treatment modality.
![Figure 5 Rankogram of interested treatment modality.](/cms/asset/40698a7e-d0be-4b50-8edf-0fe99d02cc33/dtcr_a_162898_f0005_c.jpg)
Figure 6 Comparison of adverse events for regimens in advanced HCC OR (95% CI).
Abbreviations: CI, confidence interval; HAIC, hepatic arterial infusion chemotherapy; OR, odds ratio; SBRT, stereotactic body radiotherapy; TACE, transarterial chemoembolization; RT, radiotherapy.
![Figure 6 Comparison of adverse events for regimens in advanced HCC OR (95% CI).](/cms/asset/3118cd23-32a4-4c51-90db-221bc00ad31f/dtcr_a_162898_f0006_c.jpg)